Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL468072 | 0.74 | METAP2 (0.33) | KIF11MAPTCYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL15090698 | 0.74 | ALOX5 (0.36) | MAPTLMNACYP1A2CYP2C19CYP2C9 | |
| SCHEMBL330399 | 0.71 | ALDH1A1 (0.44) | MAPTLMNAHTTCYP1A2CYP2C19 | |
| SCHEMBL468174 | 0.69 | ALOX5 (0.41) | MAPTLMNAHTTNPSR1CYP1A2 | |
| SCHEMBL557949 | 0.69 | KDM4E (0.36) | MAPTLMNAHTTCYP1A2CYP2C19 | |
| SCHEMBL11133162 | 0.69 | TDO2 (0.53) | KIF11POLBMAPTTSHRENPP1 | |
| SCHEMBL10000412 | 0.69 | KIF11 (0.44) | KIF11POLBMAPTTSHRENPP1 | |
| SCHEMBL3755982 | 0.67 | HSD11B1 (0.48) | CYP1A2CYP2C19CYP2C9ALDH1A1L3MBTL1 | |
| SCHEMBL332040 | 0.67 | ALDH1A1 (0.58) | POLBMAPTENPP1LMNAHTT | |
| SCHEMBL5949961 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-07-30 | — | — | US | claimed |
| CN-100490793-C | Remedies for neurodegenerative diseases | INST MED MOLECULAR DESIGN INC (JP) | 2009-05-27 | — | — | CN | claimed |
| CN-100464742-C | NF-kB activation inhibitor | INST MED MOLECULAR DESIGN INC (JP) | 2009-03-04 | — | — | CN | claimed |
| US-20080311074-A1 | Inhibitors against activation of NF-kappaB | INSTITUTE OF MEDICAL MOLECULAR DESIGN INC. (JP) | 2008-12-18 | — | — | US | claimed |
| US-20080249071-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-10-09 | — | — | US | claimed |
| US-20080234233-A1 | MEDICAMENT FOR TREATMENT OF NEURODEGENERATIVE DISEASES | INSTITUTE OF MEDICINAL MOLECULAR DESIGN INC. (JP) | 2008-09-25 | — | — | US | claimed |
| CN-101125138-A | Inhibitors against the production and release of inflammatory cytokines | INST MED MOLECULAR DESIGN INC (JP) | 2008-02-20 | — | — | CN | claimed |
| EP-1847263-A2 | Inhibitors against the production and release of inflammatory cytokines | Institute of Medicinal Molecular Design, Inc. (JP) | 2007-10-24 | — | — | EP | claimed |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-02-22 | — | — | US | claimed |
| US-20060280894-A1 | Metal complexes as light-absorbing compounds in the information layer of optical data carriers | LANXESS DEUTSCHLAND GMBH (DE) | 2006-12-14 | — | — | US | claimed |
| CN-1826106-A | Therapeutic agent for skin pigmentation | INST MED MOLECULAR DESIGN INC (JP) | 2006-08-30 | — | — | CN | claimed |
| EP-1649852-A1 | CHROMATOSIS REMEDIES | Institute of Medicinal Molecular Design, Inc. (JP) | 2006-04-26 | — | — | EP | claimed |
| CN-1748004-A | Azo metal dyes and optical data carriers containing such azo metal dyes as light-absorbing compounds in the information layer | LANXESS DEUTSCHLAND GMBH (DE) | 2006-03-15 | — | — | CN | claimed |
| EP-1599548-A1 | METAL COMPLEXES AS LIGHT-ABSORBING COMPOUNDS IN THE INFORMATION LAYER OF OPTICAL DATA CARRIERS | LANXESS Deutschland GmbH (DE) | 2005-11-30 | — | — | EP | claimed |
| EP-1597321-A1 | AZO METAL DYES AND OPTICAL DATA CARRIER CONTAINING ONE SUCH AZO METAL DYE AS A LIGHT ABSORBING COMPOUND IN THE INFORMATION LAYER | LANXESS Deutschland GmbH (DE) | 2005-11-23 | — | — | EP | claimed |
| WO-2004072185-A1 | AZO METAL DYES AND OPTICAL DATA CARRIER CONTAINING ONE SUCH AZO METAL DYE AS A LIGHT ABSORBING COMPOUND IN THE INFORMATION LAYER | LANXESS DEUTSCHLAND GMBH (DE) | 2004-08-26 | — | — | WO | claimed |
| WO-2004072184-A1 | METAL COMPLEXES AS LIGHT-ABSORBING COMPOUNDS IN THE INFORMATION LAYER OF OPTICAL DATA CARRIERS | LANXESS DEUTSCHLAND GMBH (DE) | 2004-08-26 | — | — | WO | claimed |
| US-8263657-B2 | Blocking neurokinins; using a benzene compound containing hydroxy or acetoxy group; antiinflammatory agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-09-11 | — | — | US | disclosed |
| CN-1489458-A | Inflammatory cytokine production dissociation inhibitor | ��ʽ����ҽҩ��������о��� | 2004-04-14 | — | — | CN | disclosed |
| EP-1352650-A1 | INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES | Institute of Medicinal Molecular Design, Inc. (JP) | 2003-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311074-A1 | Inhibitors against activation of NF-kappaB | NFKBIA, IKBKB, RELA | KIF11 4578/4885POLB 275/4885MAPT 2581/4885 |
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | KIF11 4810/4885POLB 3109/4885MAPT 2086/4885 |
| US-20080249071-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | KIF11 4810/4885POLB 3109/4885MAPT 2086/4885 |
| US-20080234233-A1 | MEDICAMENT FOR TREATMENT OF NEURODEGENERATIVE DISEASES | MAPT, TFEB, MAOA | KIF11 4342/4885POLB 2533/4885MAPT 1/4885 |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | TYR, XDH, XPA | KIF11 4555/4885POLB 1349/4885MAPT 3082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.